Lenva 10 mg (Capsule)
Unit Price: ৳ 1,750.00 (2 x 6: ৳ 21,000.00)
Strip Price: ৳ 10,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lenvatinib mesylate |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Differentiated Thyroid Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Endometrial Carcinoma
Pharmacology
- Kinase inhibitor
- VEGFR inhibition
- FGFR inhibition
- PDGFR inhibition
- Antiproliferative activity
Absorption
Time to peak plasma concentration (Tmax) is 1 to 4 hours post-dose. Administration with a high-fat meal does not affect the extent of absorption.
Distribution
- In vitro binding to human plasma proteins
- Blood-to-plasma concentration ratio
Metabolism
- Enzymatic and non-enzymatic processes
- Identified metabolic pathways (CYP3A and aldehyde oxidase)
Elimination
Approximately 64% eliminated in the feces and 25% in the urine after a single administration
Dosage
- Dose reduction for certain patients
- Different recommended dosages for specific indications
Administration
- Capsules can be swallowed whole or dissolved in liquid
- Instructions for dissolving in liquid
Interaction
Lenva prolongs the QT/QTc interval. Avoid coadministration with drugs that prolong the QT interval
Contraindications
Contraindicated in patients with known hypersensitivity to Lenvatinib or any component of the formulation
Side Effects
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal failure and impairment
- Diarrhea
- Fistula formation and gastrointestinal perforation
- QT Interval Prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhagic events
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction
- Wound healing complications
Pregnancy & Lactation
- Potential embryo-fetal harm during pregnancy
- Recommendation to use effective contraception
- Discontinuation of breastfeeding during treatment with Lenvatinib
Precautions & Warnings
- Hypertension monitoring and control
- Monitoring for cardiac dysfunction
- Monitoring for arterial thromboembolic events
- Monitoring of liver function
- Monitoring for renal failure or impairment
- Monitoring for proteinuria
- Management of diarrhea
- Management of fistula formation and gastrointestinal perforation
- Electrolyte abnormalities monitoring
- Treatment of hypothyroidism
- Wound healing precautions
Use in Special Populations
- Dosage modifications for severe renal impairment
- Dosage modifications for severe hepatic impairment
- Pediatric use disclaimer
Overdose Effects
Not expected to be dialyzable due to high plasma protein binding. Death due to multiorgan dysfunction reported with a single dose of 120 mg orally
Storage Conditions
Store below 30°C in a dry place. Protect from light and keep out of the reach of children